Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
Department of Gastroenterology, São João Hospital Center, Porto, Portugal.
United European Gastroenterol J. 2020 Aug;8(7):755-763. doi: 10.1177/2050640620935732. Epub 2020 Jun 18.
The increasing knowledge on ulcerative colitis' pathophysiology has contributed to the expansion of the therapeutic arsenal for this condition. However, to date, 25-40% of patients with ulcerative colitis remain primary or secondary non-responders to therapy, and up to 10% need to eventually undergo a colectomy. Janus kinase inhibitors block cytokine signalling involved in the pathogenesis of several inflammatory conditions. Tofacitinib is the first drug of this class approved for moderate-to-severely active ulcerative colitis in patients for whom disease worsened and those who did not improve with conventional therapy (aminosalicylates, corticosteroids and immunosuppressants) or monoclonal antibodies. We aimed to review the main aspects and concerns related to the current use of tofacitinib and to explore its future application.
溃疡性结肠炎的发病机制的相关知识不断增加，这促进了治疗这种疾病的方法的扩展。然而，迄今为止，25-40%的溃疡性结肠炎患者对治疗仍为原发性或继发性无应答，多达 10%的患者最终需要进行结肠切除术。Janus 激酶抑制剂可阻断几种炎症性疾病发病机制中涉及的细胞因子信号传导。托法替尼是首个获批用于中重度活动期溃疡性结肠炎的此类药物，适用于疾病恶化且对常规治疗（氨基水杨酸类药物、皮质类固醇和免疫抑制剂）或单克隆抗体治疗无应答的患者。我们旨在综述当前托法替尼应用的主要方面和关注点，并探讨其未来的应用。
